Systemic lupus erythematosus (SLE) is a very complex disease where multiple immunological pathways can concur in inducing tissue damage. Cytokines are key mediators in this process and among them the role of interleukin (IL)-12 and the IL-23/Th17 axis has recently emerged. IL-12 and IL-23 have a heterodimeric structure with a common subunit, named p40. Although they share a partially common structure, their functions appear slightly different. Indeed, IL-12 is a key cytokine in inducing an efficient T helper 1 (Th1) response and in Th differentiation, while IL-23 plays a crucial role in chronic inflammation and Th17 cell activation, which results in IL-17 secretion. The increasing knowledge on the interaction between IL-12 and IL-23/Th17 axis in the development of autoimmune diseases has led to the identification of new therapeutic strategies targeting these immunological pathways. IL-23/Th17 axis has recently been suggested to be essential in developing lupus nephritis, both in mice and in humans. In keeping with these observations, ustekinumab, a fully human IgG1j monoclonal antibody (mAb) directed towards p40 subunit, has been investigated in SLE. Promising data from a phase II randomized controlled trial in SLE patients suggest that this mAb might be a potential novel therapeutic strategy in SLE. In this review, we summarize the complex interaction between IL-12 and IL-23/Th17 axis in SLE with a special focus on drugs which affect this immune pathway.
Introduction
Systemic lupus erythematosus (SLE) is a rheumatic autoimmune disease characterized by a loss of self-tolerance leading to the development of autoantibodies (auto-Abs) directed towards ubiquitous nuclear self-antigens, which in turn can induce immune complex (IC) formation, and eventually organ damage. 1 The production of auto-Abs is enhanced by several mechanisms, including abnormal clearance of apoptotic material. 1, 2 Studies on animal models have recently provided novel insights into the mechanisms leading to SLE occurrence (Table 1) . It has been shown that the interleukin (IL)-17/interferon (IFN) type 1 interplay is crucial in the recruitment of immune cells into the kidney and in the formation of the inflammatory infiltrate in lupus nephritis (LN): indeed, lupus-prone IL-17A receptor (IL-17RA) deficient mice develop an IFN type I-dependent LN milder than control mice. 3, 4 The interaction between IL-12 and IL-23/T helper 17 (Th17) axis has recently been shown to be involved in SLE progression, which could pave the way for new therapeutic targeted strategies in SLE.
To our knowledge, no reviews simultaneously focusing on the interaction between Il-12, IL-23, and IL-17, as well as
Impact statement
Our article is focused on emerging pathogenetic pathways in systemic lupus erythematosus (SLE). Notably, IL-12 and IL-23 have been described as emerging cytokines in SLE pathogenesis. We know that IL-23 stimulates Th17 cells to produce IL-17. We try to point out the importance of IL-23/Th17 axis in SLE and to focus on the interaction between this axis and IL-12. Ustekinumab, a fully human IgG1j monoclonal antibody directed towards the p40 shared subunit of IL-12 and IL-23, has been recently investigated in SLE, suggesting a potential novel therapeutic strategy in SLE. To our knowledge, there are no reviews which simultaneously focus on IL-12 an IL-23/Th17 axis in SLE. Thus, we believe our work will be of interest to the readers. Table 1 . Summary of murine studies using genetically modified mice by targeting IL-12, IL-23, and IL-17. Highly susceptible to CIA 6 Enhanced EAU is associated with increased systemic and local IL-17 responses 7 Develop less severe cGN than wildtype animals 8 Administration of
IL23 to p40
-/-mice infected with T. gondii result in a decreased parasite burden and enhanced resistance 9 Mice are resistant to CIA induction 6 High resistance to CIA induction 6 More 14 IL-12 is composed by an heterodimeric structure of 70 kDa, which includes two covalently linked subunits, namely p40 (IL-12B) and p35 (IL-12A). 15 The expression of the p35 and p40 genes is independently regulated. 15 Indeed, p35 subunit is tightly regulated and requires the expression of p40 for the secretion of the biologically active cytokines. 16 By contrast, the expression of p40 subunit is higher than that required for p35p40 assembly. 17 IL-12 is released by innate immune cells upon microbial stimulation (discussed below) subsequently binding to IL-12R. The structure of IL-12R includes two different chains, i.e. IL-12b1R and IL-12b2R. 15 The interaction between IL-12 and IL-12R stimulates the non-receptor Janus Kinase 2 (JAK2) and tyrosine kinase 2 (TYK2) activity, leading to the phosphorylation of signal transducer and activator of transcription (STAT) family members, i.e. STAT1, STAT3, STAT5, and mostly STAT4 homodimers. 18 As demonstrated both in vitro and in vivo, 19, 20 free p40 can form homodimers or persist as free monomers, both of which have been proposed as natural inhibitors of IL-12. 21 Some differences in p40 homodimers have been found between human and mice.
14 In mouse models, p40 homodimers are not biologically active, but they bind the b1 subunit of IL-12 receptor (IL-12 b1R) with an affinity similar to p40 heterodimers; hence, p40 homodimers and heterodimers can compete for IL-12-b1R 21 and homodimers can be considered as natural inhibitors of IL-12 activity. 14, 21 However, in humans, p40 homodimers bind IL-12b1R with a lower affinity compared with heterodimers; hence, IL-12p40 homodimer cannot be considered a physiological antagonist of IL-12 in humans. 14 
IL-12 functions in immune response
IL-12 accomplishes different functions as summarized in Figure 1 , and represents the "bridge" between the innate and the adaptive immune system. 15 IL-12 is a pro-inflammatory cytokine which induces Th cells differentiation into Th1 cells. 14, 22 However, the absolute requirement of IL-12 in Th1 induction was questioned, 3, 23 suggesting that it may rather be part of a broader machinery leading to Th1 differentiation through induction of IFN c 24 as well as of T-bet, 23 in the frame of overlapping pathways finally culminating in a robust Th1 expansion. 24 Several authors observed the inhibition of Th1 cell response in animals treated with neutralizing Abs targeting IL-12p40, IL-12p35, IL-12b1R, IL-12b2R or STAT4. 14 IL-12 has an important role in the defense against microbial agents, particularly in the protection from intracellular parasites.
14,15,25 IL-12 is rapidly secreted by dendritic cells (DCs) stimulated by toll like receptor (TLR) ligands, such as lipopolysaccharides (LPS), oligodeoxynucleotides (CpG), and polyinosinic-polycytidylic acid. 26 Macrophages can also produce IL-12 after being stimulated by microbial and bacterial products, or even by T cells through CD40-CD40L interactions. 27, 28 Once IL-12 has been released, it mediates the differentiation of Th cells into Th1 cells, which are mainly responsible for antimicrobial responses through the production of IFN-c. 14 The role of IL-12 and IFN-c in sustaining Th1 responses has further been investigated in mice, both in vitro and in vivo. 29, 30 The p40-deficient mice were found to be more suppressed than p35-deficient mice in terms of their ability of resisting to mycobacterial infections. 29, 30 IL-12 also induces various cytotoxicity pathways and the expression of cytotoxic mediators 14 by amplifying the production of IFN-c. 14, 18, 31 Notably, IL-12 can activate natural killer (NK) cells, generate lymphokine-activated killer (LAK) cells, and it is involved in the generation of cytotoxic T lymphocytes. Only few studies evaluated IL-12 function on B-cell response, 15 likely due to the difficulty in blocking IL-12 responsiveness in B cells without blocking T cells. 15 There are some evidence that IL-12 can directly bind B cells, having either stimulatory or inhibitory effect. The stimulatory effect leads to IL-12-dependent differentiation of B cells into plasma cells secreting high levels of immunoglobulin M (IgM); the inhibitory effect induces loss of peritoneal B cells. 34 Finally, as reported by Trinchieri et al., 14 hematopoietic progenitors are also targets of IL-12, in synergy with other colony-stimulating factors (CSF).
IL-12 in SLE
SLE genetic risk tends to be associated with IL-12/IL-12R pathway (IL12A, IL12B, IL12RB2, TYK2, STAT4). 35, 36 A complex polymorphism in the promoter region of the IL-12B (IL12Bpro), resulting from four base-paired micro-insertion combined with an AA/GC transition (rs17860508), was found to be associated with SLE development in Bulgarian as well as Polish population. 37, 38 Higher levels of IL-12 were observed in SLE patients compared to controls 32, 39 and p40 subunit serum levels were found to be positively correlated with SLE Disease Activity Index (SLEDAI) and negatively with C3 serum levels. 40 Interestingly, this elevation of IL-12 is not paralleled by a consistent increase of Th1-cytokines including IFNc, whose serum levels are rather lowered, 39 suggesting a down-regulation of the Th1 phenotype in favor of a Th17 phenotype 41 (discussed below). A dysregulation of IL-12 subunit expression was reported in SLE patients. 42, 43 IL-12p35mRNA expression in peripheral blood mononuclear cells was found to be significantly lower in SLE patients, either untreated or treated, than in healthy controls 42 ; however, they were found to be higher in active SLE patients compared to inactive ones. 42 Interestingly, corticosteroids or corticosteroids plus immunosuppressants significantly suppressed IL-12p40 expression in SLE patients. 42, 44 T-follicular helper (Tfh) cells are critical in the development and progression of SLE and a recent study 43 suggested that IL-12-mediated co-activation of STAT1 and STAT4 altered histone modification, resulting in differentiation of T-follicular helper-Th1-like (Tfh-Th1) cells. This could be one of the underlying mechanisms responsible for the expansion of Tfh-Th1-like cells and potentially targeted by specific treatment.
IL-23/Th17 axis
The IL-23/Th17 axis is emerging as a critical regulatory system that bridges the innate and adaptive arms of the immune system and plays a critical role in the development of autoimmune inflammatory diseases.
IL-23
IL-23: Overall characteristics and structure. IL-23 is produced by macrophages, DCs, keratinocytes, and other antigen-presenting cells as well as T and NK lymphocytes, and it is mainly involved in the expansion of Th1-Th17 cells. 18, 45 Likewise IL-12, IL-23 consists of a heterodimeric structure, comprising p19 and p40 subunits. The p40 chain is shared with IL-12, 15, 18, 45 whereas IL-23p19 subunit is specific of IL-23.
Once IL-23 is secreted, it binds to IL-23 receptor which consists of two different receptor chains 45 : IL-12b1R and one receptor chain specific of IL-23, named IL-23 receptor (IL-23R). The first subunit is a glycosylated type I membrane protein of 70.5 kDa (in mice 79.7 kDa), which includes five extracellular domains, a single transmembrane domain and a cytoplasmic domain. 45 Since IL-12b1R is an essential component of both IL-12R and IL-23R, its deficiency will affect both IL-12 and IL-23-dependent innate and adaptive immune response. By contrast, IL-23 does not bind IL-12b2R (that is the second specific chain of IL-12R), suggesting that an additional IL-23 receptor chain is required. 46 The second subunit, IL-23R, is a glycosylated type I membrane protein of 69 kDa (in mice 70.7 kDa) with three extracellular domains, a 37-aminoacid long-stalk region, a single transmembrane domain and a cytoplasmic domain. 45 As for IL-12, IL-23 signaling depends on the activation of TYK2 (via IL-12b1R) and JAK2 (via IL-23R), which predominantly phosphorylate STAT3 and to a lesser extent STAT1, STAT4, and STAT5. IL-23 leads naïve CD4þ T cells to differentiate into Th17 cells, 46 which have intimately been associated with the development of autoimmune diseases. 6 In addition, IL-23 has recently emerged as a key player in chronic inflammation, 15 as shown by studies carried out in a murine model of multiple sclerosis (MS). 5, 47 Indeed, IL-23-deficient (p19-/-) mice were resistant to central nervous system inflammation, and they were able to develop Th1 cell response, but not Th17 cell response. 48 IL-23 is also essential in developing collagen-induced arthritis (CIA), a rodent model of rheumatoid arthritis (RA). 6 Interestingly, IL-23 gene-targeted mice (p35-/-or p19-/-) did not develop clinical signs of disease and were completely resistant to the development of joint and bone damage. 6 Conversely, IL-12 appeared to protect animals from developing CIA. 6 IL-23 and IL-12 act as complementary cytokines in the protection against infectious agents. As reported above, IL-12 is essential in the response to intracellular pathogens; by contrast, the role of IL-23 in immune response against these pathogens is less clear. 15 It has to be noted that IL-23 production in response to microbial infections is less dependent from IFN-c than that of IL-12. 15 Indeed, IFN-c only slightly enhances IL-23 expression in type 1 macrophages and IFNc is not required by DCs in order to produce IL-23 in response to microbial stimulation.
Increased serum levels of IL-23 were observed in systemic sclerosis, RA, SLE, primary antiphospholipid syndrome, spondyloarthropathies, and inflammatory bowel diseases. 49 IL-23 in SLE. IL-23 has recently emerged as a key cytokine in the pathogenesis of SLE. 41 Some authors found that mRNA levels of p19, p40, and p35 were significantly higher in active SLE patients than in patients with inactive SLE. 41 IL-23 has been investigated in LN, either in humans or mice. A number of studies reported high IL-23 serum levels in SLE patients with LN 50, 51 and an expansion of T cells, expressing both high IL-23 and IL-17 receptors in lupusprone mice. 52 Zhang et al. 52 found that lupus-prone B6/lpr-derived lymphnode cells expressed IL-23R mRNA. Treating these cells with IL-23, they observed a manifold increase in the expression of IL-23R and IL-17A with a significant correlation with IL-17A mRNA levels. 52 The transfer of IL-23-treated lymphocytes in Rag-1À/À mice led to a significant increase in proteinuria and to the appearance of white blood cells in the urine sediment. By contrast, mice transplanted with B6-derived lymphocytes untreated with IL-23 did not show significant proteinuria or leukocyturia. 52 IL-23R deficiency has been found to prevent the development of LN in mice. 12 Several studies investigated the role of IL-23 in the pathogenesis of SLE and its relationship with disease activity. [48] [49] [50] 52 Concerning LN, glomerular IL-23 expression was found to be positively correlated with renal SLEDAI and histologic activity index. 47 The relationship between IL-23 and LN is also supported by the observation that patients with LN who were British Isles Lupus Assessment Group (BILAG)-non-responders had high IL-23 serum levels at baseline. 54 Apart from LN, high IL-23 serum levels were shown to be associated with other SLE manifestations in humans, including cutaneous involvement and serositis. 53 Interestingly, high IL-23 serum levels were also associated with obesity and atherosclerotic plaques. 49, 50, 53 A significant correlation between IL-23 serum levels and antiphospholipid antibodies (aPL) was observed. 49 IL-23 serum levels were found to be correlated with IFNk1 and associated with anti-nucleosome antibodies, lymphopenia, and absence of musculoskeletal damage. 48 Moreover, patients with high levels of IL-23, IFN-k1, and IL-17A had more disease damage, especially in renal domain. 48 IL-23 mRNA serum levels were found to be elevated in Asian SLE patients with renal disease. 55 Dai et al. 56 observed that when IL-23 is added to T cells from SLE patients in vitro, it induces the production of IL-17, while concomitantly limiting that of the regulatory cytokine IL-2, thus resulting in an expansion of T follicular helper and double negative (DN) T cells and worsened inflammation. The same authors generated IL-23 receptordeficient MRL/lpr mice which displayed attenuated LN with a striking decrease in the accumulation of DN T cells in the kidneys and secondary lymphoid organs. Moreover, T cells from IL-23R-/-MRL/lpr mice produced increased amounts of IL-2 and reduced amounts of IL-17 compared with T cells from wild-type animals. 56 
Th17
Th17: Overall characteristics. Th17 lymphocytes are an important, new subset of Th cells which play a major role in autoimmunity. They derive from naïve CD4þ T cells and are characterized by the expression of the transcription factor named "related orphan receptor gamma" (RORcT). 57, 58 Once stimulated by different cytokines including IL-23, 4 Th17 secrete cytokines, i.e. IL-17 family members as well as IL-21, IL-22, tumor necrosis factor (TNF)-a, and IL-6.
57
Th17 in immune response. The interaction between IL-23/Th17 and Th1 cells has recently been shown to be involved in renal injury. 59 Odobasic et al. 8 found that mice deficient in IL-17A or IL-23 were protected in the early stage of anti-glomerular basement membrane (GBM) nephritis, whereas IL-12-knockout mice lacking Th1 response were protected in the later stages. Hence, Th17 response seems to be an early effector of the disease, whereas Th1 immune response acts as a late effector at least in models of crescent glomerulonephritis. 8 Renal cd T cells were shown to be the primary source of IL-17 production in the early stage of nephrotic syndrome due to immunemediated glomerular diseases. 60 In a following step, CD4þ Th17 cells infiltrate the kidney and secrete IL-17, and thereafter Th17 cell response declines and Th1 immune response increases. 60 In contrast to Th1 and Th2 cells which are considered stable lineages, Th17 cells exhibit high degree of plasticity. 61 This concept deals with the possibility that CD4þ IL-17 producing T cells can potentially acquire features of Th1 or, alternatively, T regulatory (reg) cells. 61 Indeed, a small proportion of human peripheral Treg cells produce IL-17 in healthy people. 62 Whether Th17-like Treg cells are a transient stage in the differentiation of Treg into Th17 cells remains to be determined, 62 although this conversion has been described in several experimental models both in CIA and in mouse models of psoriasis. 62 Due to their opposite effects on the immune response, Th17/Treg balance is critical in maintaining immune homeostasis, and if Treg cells are defective, they can be converted into Th17 cells leading to inflammatory diseases. 63, 64 However, other studies showed that Th17 plasticity is typical of Th17 cells in central nervous system and intestine, 65, 66 but it does not seem to occur in kidney, where a unique microenvironment enables Th17 cells to maintain their phenotype. 60 In addition, Th17 cells are involved in several functions including protection against extracellular bacteria, viruses, and fungi via the production of IL-17.
67
Th17 cells play a crucial role in the IL-23/Th17 axis, which has been recently shown to be involved in the pathogenesis of asthma, psoriasis, inflammatory bowel disease, and some autoimmune diseases including MS, RA and SLE. 15, 68 Th17 in SLE. An increase in Th17 cells and IL-23 serum levels was detected in SLE patients compared with healthy controls. 53 Chen et al. 50 found that the frequency of circulating Th17 cells as well as IL-17 and IL-23 serum levels was higher in patients with LN compared with controls. In the same study, circulating Th17 frequency was found to be correlated with SLE activity, in particular with SLEDAI, renal SLEDAI, and histological activity index, 50 consistently with previous findings. 39 The potent proinflammatory activities of Th17 cells can contribute to several pathological pathways of SLE, such as the induction of vascular inflammation, recruitment of leukocytes, activation of B cells, and autoAbs production. 68, 69 Notably, hydroxychloroquine was shown to inhibit the differentiation of Th17 cells which could potentially explain the beneficial effects of this drug in SLE treatment, 70 while Th17 may be involved in resistance to glucocorticoid treatment in SLE through secretion of proinflammatory cytokines. 71 Regarding experimental models, Th17 cells were also shown to be increased in MRL/lpr mice. 72 In a pristaneinduced mouse model of SLE bearing a specific deletion of STAT3-dependent Tregs, Kluger et al. found an overshooting Th17 response associated with a worsening of LN at four and nine months after pristane injection. 67 Tregs deficiency was also found to be associated with pulmonary vasculitis and a significant higher mortality. Hence, STAT3 Treg has been speculated to be the novel anti-inflammatory mediators in SLE. 67 
IL-17
IL-17: Overall characteristics and structure IL-17 is a family of cytokines, produced by Th17 lineage, which includes IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25), and IL-17F. 73 IL-17A is the most studied, 63 while the contribution of the other Th17 cell-derived cytokines has to be fully elucidated yet, especially regarding IL-17B, C and D. 61, 63 IL-25 has the lowest homology and is involved in Th2 cell responses against parasites and allergy. 63 IL-25 regulates IL-17 function, which may occur via a competition at the receptor level. 63 Homodimers and heterodimers of IL-17 cytokines signal via a dimeric IL-17Rs, which consist of five identified subunits (IL-17A to E). 63 The precise binding affinity and downstream signal of the various IL-17Rs have not been elucidated yet. However, the blockade of different IL-17 cytokines or their receptors can quantitatively and qualitatively yield different biologic effects. 74 IL-17A, IL-17F bind the same receptor complex composed of IL-17RA and IL-17RC subunits. 63 IL-17RA is also one of the receptor subunits of IL-25, which includes IL-17RA and IL-17RB. 63 This is important when targeting IL-17RA, which blocks the proinflammatory pathways mediated by IL-17A, IL-17F but also the antiinflammatory response mediated by IL-25. 64 
IL-17 in immune response
IL-17 has been shown to be involved in various inflammatory processes, and it has a pivotal role in the initiation and development of autoimmunity. 57 IL-17 deficiency leads to a lower control of infections, but its overproduction can lead to several chronic inflammatory and autoimmune diseases. 63 IL-17 induces the production of inflammatory cytokines (namely TNF, IL-1b, and IL-6), different CSF, i.e. granulocyte (G)-CSF and granulocyte-macrophage (GM)-CSF, and chemokines (CXCL-8 and CXCL-2). 75 One of the main functions of IL-17 family cytokines is the induction of metalloproteinases (MMP) leading to tissues degradation. 16 Besides, IL-17 stimulates different cellular populations including fibroblasts, endothelial and epithelial cells, keratinocytes, and macrophages to produce several cytokines, including TNFa, which activate and attract neutrophils into the site of inflammation. 32 IL-17 is a driving cytokine in the rheumatoid synovitis, psoriasis, and uveitis as well as in the dysregulation of immune system, leading to MS and other autoimmune diseases. 48, 54 Mice genetically deficient for IL-17A were found to be less susceptible to the development of CIA or EAE. 76 IL-17 seems to be involved in autoimmune glomerulonephritis. 77, 78 It has been suggested that IL-17R-knockout mice were protected from crescent formation but not from glomerular necrosis or renal interstitial injury. 77, 78 The role of other IL-17 cytokine family members and their receptors in inflammatory nephropathies remains unclear. 61 
IL-17 in SLE
IL-17 has been speculated to be essential in the development of LN. Indeed, pioneering works in 2009 demonstrated the presence of IL-17 producing T cells in Fas/lpr mice, a model of spontaneous lupus with renal involvement, previously thought to be mediated by IFN-c-producing T cells. 51, 52 IL-17 was in fact shown to exert detrimental effects on intrinsic renal cells in either mice models of diverse autoimmune-nephropathies and humans, namely endothelial cells, tubular epithelial cells, mesangial cells, and fibroblasts where it can enhance the production of neutrophil-attracting chemokines and induce direct apoptosis of podocytes in mice. 79 Interestingly, CD3þ T cells, which are double negative for CD4 and CD8 expression, were found to be the main source of IL-17 in MRL/lpr mice. 52 The same authors showed an expansion of T cells expressing both high IL-17 and IL-23R, 52 and they found that lymphocytes isolated from MRL/lpr mice progressively expressed higher levels of IL-17R and IL-23R mRNA as their disease became more severe. 52 In pristane mouse model, the induction of SLE did not occur in IL-17-deficient mice which were protected from developing auto-Abs and LN, compared to control mice. 80, 81 In addition, the up-regulation of Th17 response due to impaired Treg cell function led to a worsening of ............................................................................................................................................................   LN . 80, 81 Consistently, treatment of a systemic model of SLE, i.e. MRL/lpr lupus mice with anti-IL-23 mAbs ameliorated LN 82 and was associated with a decrease in IL-17 serum levels without any significant change in Th1 activity. Taken together, these findings suggest that signaling of IL-17A worsens LN and may further emphasize that IL-17-producing T cells play a pivotal role in LN. 82 On the other hand, Schmidt et al. 83 showed that anti-IL-17 treatment did not affect the course of LN in NZB/NZW mice, whereas anti-IFN-c treatment attenuated the severity of disease, suggesting a predominance of Th1 immune response in these lupus mouse models. Thus, a different genetic background might account for these discrepancies, suggesting Th17 and Th1 cell responses might contribute to LN by distinct pathways. 61 These differences could also explain the divergent response to the treatment of these mice when treated with Th17-or Th1-targeted therapies. 61 Concerning humans, serum levels of IL-17 were shown to be higher in SLE patients compared to controls, 39, 54 and an increased IL-17 expression was documented in inflammatory infiltrates in renal tissue of patients with active LN. 54 High IL-17 serum levels were shown to be a marker of adverse histopathological outcome after immunosuppressive therapy in LN, indicating that IL-17 production could be associated with a severe or therapy-resistant disease phenotype. 16 In renal biopsies of LN, IL-17A, and IL-23 expression was demonstrated in DN, CD4, and CD8 T cells 84 ; in addition, glomerular IL-17A and IL-23 were found to be positively correlated with renal SLEDAI and histological activity index, 50 while a negative correlation of IL-17 with chronicity index was reported, 85 suggesting IL-17 may act at early stages of inflammation in LN.
Finally, Abdel Galil et al. 86 observed a positive correlation between IL-17 serum levels and proteinuria or antidouble strand DNA antibodies (anti-dsDNA ab) in patients with LN, suggesting a potential pathogenetic link between the IL-23/Th17 axis and SLE activity. 61 
New therapeutic strategies in SLE
Increasing knowledge in the IL-12 and IL-23/Th17 axis in inflammatory autoimmune diseases has led to develop novel therapeutic strategies targeted to such molecules. 74 There are different strategies to block IL-17 including monoclonal antibodies directed against IL-17, IL-17R, IL-12/23p40, and IL-23p19. 74 Ustekinumab (Stelara V R ; Janssen Biotech, Inc., Horsham, PA), is a fully human IgG1j mAb directed against the shared p40 subunit of IL-12 and IL-23. 74, 87 By linking this subunit, it precludes the binding to IL-12Rb1 cell surface receptor, thereby hindering the activity of both cytokines. 88 Ustekinumab has been recently approved by the U.S. Food and Drug Administration and the European Medicines Agency for different autoimmune diseases, including psoriasis, psoriatic arthritis, 89 and Chron's disease. 87, 88 It is currently under evaluation in SLE since a decrease in disease activity was observed in animal models lacking the shared IL-12/23 p40 subunit, suggesting this could be a potential target also in humans. 54 Phase III and other clinical trials confirmed the efficacy of this novel mAb in treating moderate to severe plaque psoriasis, [89] [90] [91] where ustekinumab was even superior to anti-TNFa agents. A meta-analysis showed that the likelihood expressed as risk ratio (RR) for achieving psoriasis area and severity index improvement by 75% (PASI75) at week 12 was 18.28 (95% CI 12.76-26.17 p < 0.001) for ustekinumab 45 mg compared to placebo and 20.21 (95% CI 13.85-29.49 p < 0.001) for ustekinumab 90 mg compared to placebo. 92 Ustekinumab is under investigation in SLE patients and very promising data were recently disclosed. In a phase II RCT carried out in active SLE patients, 93 ustekinumab was found to be superior to placebo in terms of SLE Responder Index-4 (SRI-4) response after 24 weeks (60% vs. 31%, p ¼ 0.0046). Ustekinumab resulted to be particularly effective in patients with skin and joint manifestations. In addition, a significant increase in C3 and a decrease in anti-dsDNA ab levels were found after treatment suggesting that ustekinumab could have an immunomodulatory effect in SLE.
Very few data on the use of IL-17 inhibitors in SLE are available. A case of a 62-year-old female who presented with psoriasis vulgaris and refractory LN treated with the anti-IL-17A mAb secukinumab was reported. 94 The patient was resistant to conventional treatment, and flow cytometry confirmed the proliferation of activated Th17 cells in peripheral blood, and examination of a renal biopsy tissue sample confirmed the infiltration of numerous IL-17-positive lymphocytes into the renal interstitium. After starting secukinumab, the clinical and biological features were improved.
Summary and conclusion
A wide variety of cytokines are involved in SLE pathogenesis. Recently, the IL-23/Th-17 axis has been identified as a key mediator of inflammation in SLE, especially in LN, as suggested by data derived from mouse models and humans. Beside this axis, it has become clear that the interaction between Th1 and Th17 cell lineages is much more interlined and complex than it was initially thought.
Ustekinumab, which target the p40 subunit of IL-12 and IL-23, might be a potential strategy for active SLE. Despite these promising findings, further studies are needed in order to define the efficacy of treatments aimed at blocking IL-12, IL-23, and IL-17 in SLE.
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